Morphic Holding Inc

Morphic — JP Morgan Healthcare Conference 2020

28 slides from Morphic's conference presentation, Jan 13, 2020

  1. Slide 1: Delivering a New Generation of Integrin Medicines

    DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES JP Morgan, January 2020 CONFIDENTIAL 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward - looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic’s plan to develop and commercialize oral small - molecule integrin t

  3. Slide 3: Unique Opportunity to Mine Integrins: Well Validated Target Class

    Unique Opportunity to Mine Integrins: Well Validated Target Class • All a pproved integrin therapies are non - oral options for a wide variety of serious chronic diseases • Estimated 2018 sales of at least $4.6 billion 1 Validated Target Class with Large Market Opportunity • Oral integrin therapies

  4. Slide 4: Building the Future of Integrin Medicines

    BLAISE LIPPA, PhD Head of Chemistry Building the Future of Integrin Medicines Deep specialist expertise across management, Board and Advisors CONFIDENTIAL 4 PRAVEEN TIPIRNENI, MD President and Chief Executive Officer BRUCE ROGERS, PhD ALEXEY A. LUGOVSKOY, PhD ADRIAN RAY, PhD Chief Scientific Officer

  5. Slide 5: The Role of Integrins

    The Role of Integrins CONFIDENTIAL A family of cell surface receptors with unique ability to signal bi - directionally Named integrins because they ‘integrate’ extracellular and intracellular stimuli They function as signal transduction platforms, mechano - sensors and adhesion molecules (e.g. leuko

  6. Slide 6: Integrin Therapies Are Applicable across a Broad Range of Chronic Diseases

    Integrin Therapies Are Applicable across a Broad Range of Chronic Diseases CONFIDENTIAL 6 Abciximab Eptifibatide Tirofiban FY 2018 Sales (1) $4.6B (1) Evaluate Pharma. Combined revenue in respective FY2018. Natalizumab Vedolizumab Lifitegrast Efalizumab

  7. Slide 7: Integrins: Conformation is Key to Function

    Integrins: Conformation is Key to Function • Integrins shift between an open and closed conformation • Morphic develops small molecules designed to lock “healthy” integrin conformations in place • Previous oral integrin inhibitors locked conformation in a “diseased” active state, leading to clinical

  8. Slide 8: In-house Platform Driving Pipeline Growth

    In - house Platform Driving Pipeline Growth CONFIDENTIAL 8 Data - driven Target Selection Proprietary Integrin Structural Analyses Tunable Candidate Design Translation Morphic has already delivered accelerated discovery work based on leveraging insights from early programs Activators & Inhibitors Cr

  9. Slide 9: Morphic: Focused on Major Chronic Conditions

    Morphic: Focused on Major Chronic Conditions Status Our Programs Indication Discovery Preclinical IND Phase 1 Product Rights MORF - 057 Target: α 4 β 7 Inflammatory bowel disease (IBD) Wholly Owned MORF - 720 Target: α v β 6 Idiopathic pulmonary fibrosis MR β 6 #2 Target: α v β 6 Primary Sclerosing

  10. Slide 10: MORF-057 Targeting α4β7 for Inflammatory Bowel Disease

    MORF - 057 Targeting α 4 β 7 for Inflammatory Bowel Disease CONFIDENTIAL 10

  11. Slide 11: α4β7: A Proven Mechanism of Action in IBD

    Sub - endothelial space - gut Vascular space - blood T - cell a 4 b 7 MAdCAM - 1 Endothelial cell Approved vedolizumab: IV only • IBD involves trafficking of α 4 β 7 + leukocytes to gut tissue via MAdCAM - 1 binding, causing inflammation • Vedolizumab (IV) inhibits this action and was approved for U

  12. Slide 12: Window of opportunity to alter course of disease

    Window of opportunity to alter course of disease MORF - 057 Aminosalicylate Oral/Topical Budesonide Corticosteroid Immunosuppressant Anti - TNF+/ - IS Vedolizumab+/ - IS Mild Moderate Severe MORF - 057 Goal: Oral Vedolizumab 1 This figure is illustrative and not based on actual data CONFIDENTIAL Ear

  13. Slide 13: MORF-057: Specifically Designed to Avoid Off-target Risk

    MORF - 057: Specifically Designed to Avoid Off - target Risk CONFIDENTIAL 13 Cell Adhesion Potency IC 50 [ nM ] α 4 β 7 MadCAM α 4 β 1 VCAM α 4 β 1 / α 4 β 7 Selectivity Ratio vedolizumab 0.03 >50,000 natalizumab 0.6 0.14 0.9 AJM - 300 138 770 5.6 MORF - 057 1.1 3,633 3,303 1. Activating α 4 β 1 ’s

  14. Slide 14: MORF-057: Pre-clinical Data: Dose-dependent Anti-inflammatory Activity

    MORF - 057: Pre - clinical Data: Dose - dependent Anti - inflammatory Activity CONFIDENTIAL • p<0.05, ** p<0.01, ***p<0.001, and ****p<0.0001 vs. vehicle by One Way Anova followed by Dunnett’s multiple comparisons • DATK32 is a mouse surrogate of the α 4 β 7 antibody vedolizumab 14 T lymphocyte homi

  15. Slide 15: Morphic-Engitix Collaboration to Identify ECM-Related Targets in Fibrostenotic IBD

    Morphic - Engitix Collaboration to Identify ECM - Related Targets in Fibrostenotic IBD CONFIDENTIAL 15 • Fibrostenotic IBD accounts for up to 30% of poorly treated Crohn’s disease cases • Tissue destruction (fistulisation) and fibrosis (fibrostenosis), disease complications of persistent inflammatio

  16. Slide 16: Targeting αvβ1 for fibrotic disease

    Targeting αvβ1 for fibrotic disease CONFIDENTIAL 16 a v β 1 a 4 β 7

  17. Slide 17: αvβ1 Inhibition Ameliorates Fibrosis in Animal Models

    α v β 1 Inhibition Ameliorates Fibrosis in Animal Models • Expressed in hepatic stellate cells, kidney fibroblasts, and lung fibroblasts • α v β 1 tool inhibitor reduces fibrosis in murine models of lung, kidney and liver fibrosis • Morphic research suggests that α v β 1 inhibitor can act independen

  18. Slide 18: Targeting αvβ8 and αvβ6 to address TGF-β mediated resistance in solid tumors

    Targeting αvβ8 and αvβ6 to address TGF - β mediated resistance in solid tumors CONFIDENTIAL 18 a v β 8

  19. Slide 19: Mechanism of Action of αvβ8 and αvβ6 in Tumors

    Mechanism of Action of α v β 8 and α v β 6 in Tumors CONFIDENTIAL 19 Promotion of proliferation and invasion, EMT, exclusion of immune cells Inhibition of T cell, NK cell and macrophage mediated anti - tumor immunity Increase in Treg numbers TdLN T cell DC Active TGF b Treg Naïve T cell α v β 8 α v

  20. Slide 20: Integrin Expression Conservation

    α v β 8 Integrin Expression Conservation CONFIDENTIAL 20 Tumor microenvironment Thymic/activated (KLRG1+) CD103+ Active TGF β Eberlein , 2015 Cui, 2018 Mu, 2002 Pozzi , 2011 Hu, 2013 Mertens - Walker, 2015 Hu, 2012 Bain, 2017; Worthington, 2011; Paidassi , 2011; Boucard - Jourdin , 2016; Fenton, 201

  21. Slide 21: αvβ6/αvβ8 Integrin Therapy for TGF-β Mediated Resistance in Solid Tumors

    α v β 8 / α v β 6 Integrin Therapy for TGF - β Mediated Resistance in Solid Tumors CONFIDENTIAL 21 Tumor infiltration Opportunity for proof of concept Inflamed Infiltrate Excluded Deserted “Immunologically ignorant” Immunological Status High mutational load IFN γ induced PD - L1 High immune infiltra

  22. Slide 22: MORF-720 Targeting αvβ6 to block TGF-β-driving fibrosis in multiple diseases

    MORF - 720 Targeting α v β 6 to block TGF - β - driving fibrosis in multiple diseases CONFIDENTIAL 22

  23. Slide 23: αvβ6: Essential Activator of TGF-β Signaling

    α v β 6 : Essential Activator of TGF - β Signaling CONFIDENTIAL 23 Latent TGF - β Active TGF - β α v β 6 TGF - β activation Fibrogenesis Chronic injury

  24. Slide 24: Morphic Oral αvβ6 Inhibitor: Strong Support for Mechanism of Action and Design

    • MORF - 720 delivers dose - dependent reductions in liver fibrosis in mice model • Shown to stabilize closed conformation of α v β 6 • Excellent multi - species PK • Highly potent and selective Morphic Oral α v β 6 Inhibitor : Strong Support for Mechanism of Action and Design CONFIDENTIAL 24 • p<0.

  25. Slide 25: Morphic Oral Integrin Inhibitor: Activity in Collagen Model of Fibrosis

    Healthy Control Disease Control Anti - a v b 6 mAb Treated Sirius Red Staining Under Polarized Light Collagen Deposition in Chronic Liver Fibrosis Model Morphic a v b 6 Inhibitor Treated Morphic Oral Integrin Inhibitor: Activity in Anti - α v β 6 mAb in Collagen Model of Fibrosis CONFIDENTIAL 25

  26. Slide 26: Morphic Oral Inhibitor: Superior in Bilirubin Model of Fibrosis

    Morphic Oral α v β 6 Inhibitor: Superior in Bilirubin Model of Fibrosis CONFIDENTIAL 26 * p<0.05, ** p<0.01, ***p<0.001, and ****p<0.0001 vs. vehicle by One Way Anova followed by Dunnett’s multiple comparisons • Bilirubin is a marker of liver tissue damage Total Plasma Bilirubin Mean ± SEM

  27. Slide 27: Backup

    Backup CONFIDENTIAL 27

  28. Slide 28: Integrins: Conformation is Key to Function

    Integrins: Conformation is Key to Function CONFIDENTIAL Extended - closed Conformation Extended - open Conformation Bent - closed Conformation α subunit subunit Springer JCB 2013, 201, 1053 - 1068; DOI: 10.1083/jcb.201212037

Morphic Holding — JP Morgan Healthcare Conference 2020 on 6ix